^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RG6123
i
Other names: RG6123, RO7172508, RG 6123, RO 7172508
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
CEA inhibitor
Related drugs:
over4years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1; N=26; Terminated; Sponsor: Hoffmann-La Roche; Completed --> Terminated; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
Trial termination • Clinical
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
5years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1; N=26; Completed; Sponsor: Hoffmann-La Roche; Terminated --> Completed
Trial completion • Clinical
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
5years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1, N=26, Completed, Hoffmann-La Roche | Terminated --> Completed
Clinical • Trial completion
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
over5years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1; N=26; Terminated; Sponsor: Hoffmann-La Roche; N=150 --> 26; Trial completion date: Dec 2020 --> Jul 2019; Recruiting --> Terminated; Trial primary completion date: Dec 2020 --> Jul 2019
Trial completion date • Trial primary completion date • Enrollment change • Trial termination • Clinical
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
over5years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1, N=26, Terminated, Hoffmann-La Roche | N=150 --> 26 | Trial completion date: Dec 2020 --> Jul 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jul 2019; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
over5years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2021 --> Dec 2020
Clinical • Trial completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
almost6years
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, Hoffmann-La Roche | Trial completion date: Apr 2020 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Dec 2020
Clinical • Trial completion date • Trial primary completion date
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
Share via
